688198 Beijing Balance Medical Technology Co., Ltd.
- 111.71
- +1.28+1.16%
Beijing Balance Medical Technology Co., Ltd. News
Bairen Medical (688198.SH) 2023 equity distribution: 0.80 yuan per share, share registration on May 27
Bairen Medical (688198.SH) issued the 2023 equity distribution implementation notice. This time, profits are distributed to Israel...
Bairen Healthcare (688198.SH): Net profit of 8.319,800 yuan in the first quarter decreased by 28.88% year-on-year
Gelonghui, April 22丨Bairen Healthcare (688198.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 76.265,200 yuan, up 17.53% year on year; net profit attributable to shareholders of listed companies was 8.3198 million yuan, down 28.88% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 6.3778 million yuan, down 29.26% year on year; basic earnings per share were 0.06 yuan.
Zhongtai Securities: Edward Evoque received FDA approval and continues to be optimistic about the commercialization prospects of tricuspid valve intervention
Recently, Edward Life Sciences announced that its tricuspid valve product Evoque has been approved by the FDA for marketing. This is the first FDA-approved tricuspid valve replacement product.
Bairen Healthcare (688198.SH): Net profit increased 20.99% year-on-year in 2023
Gelonghui, Feb. 27丨Bairen Medical (688198.SH) announced its 2023 annual performance report. During the reporting period, the company achieved annual revenue of 37,08549 million yuan, an increase of 25.64% over the previous year. The company's revenue in all three business segments achieved year-on-year growth: the heart valve replacement and repair segment increased 21.10% year on year, with artificial biological heart valve revenue increasing 27.74% year on year; the congenital heart implant interventional treatment and surgical soft tissue repair segment increased 26.88% and 29.74% year on year, respectively. The company achieved operating profit of 121.368 million yuan during the reporting period
[BT Financial Report Momentary Analysis] Bairen Medical's 2023 Third Quarter Report: Steady Growth Shows Steady Growth, R&D Investment Continues to Increase
Beijing Bairen Medical Technology Co., Ltd. (stock code: 688198) recently released its financial report for the third quarter of 2023. As a domestic technology-leading research and development platform enterprise for animal-derived implant interventional medical devices, its steady growth trend is once again reflected. During the reporting period, in the context of facing multiple challenges in the market, the company still achieved steady growth in operating income and improvement in profitability, while continuing to increase investment in R&D and strengthen technology and product advantages. In terms of assets and liabilities, as of the end of the reporting period, the company's total assets reached 1,266 billion yuan, an increase of 7.36% over the end of the previous year, showing
Bairen Medical (688198.SH): Mitral valvuloplasty ring products approved for registration
Bairen Medical (688198.SH) issued an announcement. Recently reviewed by the State Drug Administration, the company independently developed...
Bairen Medical (688198.SH): Transcatheter aortic valve system registration application accepted
Bairen Medical (688198.SH) issued an announcement. Recently, the company's product under development, Renatus, is the transducer manager...
Bairen Medical (688198.SH): Application for registration of the medial valve system through the catheter valve was accepted
Glonghui, October 20, 丨 Bairen Medical (688198.SH) announced that the company submitted a registration application for the product under development through the catheter valve middle valve system and was officially accepted by the Medical Device Technology Evaluation Center of the State Drug Administration. The system is specially designed for post-operative patients who have been implanted with various types of artificial biological heart valves. When biological valves in the body have been damaged or failed due to various reasons, require a second valve replacement and are at high risk of surgery, a new valve can be placed inside the damaged or failed valve through intervention to replace the various biological valves that have been damaged or failed. Clinical trial results show that it is being applied domestically
[Instant Analysis of BT Financial Report] Bairen Medical 2023 Interim Report: Main business revenue increased 18.95%, net profit increased 17.52% year on year
Bairen Medical (stock code: 688198) is a technology-leading animal-derived implantation medical device research and development platform enterprise in China. Its main business covers three areas: heart valve replacement and repair, implant interventional treatment for congenital heart disease, and surgical soft tissue repair. The company's technological innovation and product development will bring good news to domestic valvular disease patients. According to its 2023 interim report, Bairen Medical's main business revenue was 168 million yuan, an increase of 18.95% over 141 million yuan in the same period last year. Among them, heart valve replacement and repair treatment, congenital heart disease implant interventional treatment, and surgical soft tissue repair
Bairen Medical (688198.SH) released first-half results, net profit of 442,201 million yuan, up 18.56% year on year
Bairen Medical (688198.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Bai Ren Medical (688198.SH): it is proposed to use no more than 300 million yuan to raise funds temporarily idle for cash management.
688198.SH announced that on December 6, 2021, the company held the ninth meeting of the second session of the board of directors and the eighth meeting of the second session of the board of supervisors to examine and pass the "motion on the use of some temporarily idle funds to raise funds for cash management", agreeing that the company will not affect the implementation of the raised funds investment project and the safety of the raised funds. Use part of the temporary idle funds raised with a maximum balance of not more than 300 million yuan (including capital) for cash management, and timely purchase investments sold by financial institutions with high security, good liquidity and legal business qualifications.
Bai Ren Medical (688198.SH) plans to use no more than 300 million yuan to raise funds temporarily idle for cash management.
Zhitong Financial App News, Bai Ren Medical (688198.SH) issued a notice that under the condition of ensuring that the implementation of the raised funds investment project and the safety of the raised funds will not be affected, the company intends to use part of the temporarily idle raised funds (including capital) with a maximum balance of no more than 300 million yuan (including this amount) for cash management. Timely purchase of investment products sold by financial institutions with high security, good liquidity and legal business qualifications (including but not limited to financial products, structured deposits, time deposits, notice deposits, large certificates of deposit, etc.). Within this amount, the funds can be used on a rolling basis for a period of 12 years from the date of deliberation and approval by the company's board of directors.
Bai Jen Medical (688198.SH): 1.2 million restricted shares will be lifted on December 9.
On November 30th, 688198.SH announced the listing and circulation announcement of the strategic placement of restricted shares in the initial public offering, the number of strategic placing shares in this listing is 1.2 million shares, and the sales limit period is 24 months from the date of listing of the company's shares. The strategic placement of restricted shares will be listed and circulated on December 9, 2021.
1.2 million restricted shares of 688198.SH will be listed and circulated from December 9.
Zhitong Financial App News, Bai Jen Medical (688198.SH) issued an announcement that the restricted shares circulated in this listing are the strategic allotment restricted shares of the initial public offering, and the shareholders of the strategic placing restricted shares are Guoxin Capital Co., Ltd., the number of shares that have been lifted and applied for listing and circulation is 1.2 million shares, and the lock-up period is about to expire and will be listed and circulated on December 9, 2021.
The second batch of public offering REITs inquiry is hot, fund companies at the end of the year intensive recruitment layout of the New year market, fund afternoon tea
1. Newsletter 1. Subscriptions are more than 40 times the second batch of public offering REITs inquiry hot second batch of public offering REITs inquiry results have been released, subscription times are more than 40 times. In addition, from the price point of view, the institutional quotation is basically close to the upper limit of the inquiry announcement, indicating that institutional investors are enthusiastically pursuing the public offering REITs. In addition to the active participation of institutional investors, individual investors are also competing to enter the public offering REITs market. After more than half a year of operation, the structure of the first batch of public REITs holders has also changed, and individual investors are increasing significantly. The size of 2.FOF fund is expected to exceed 200.
Shen Wanhongyuan: the market share of bovine pericardial valve "increased" rating by 688198.SH is expected to increase.
Zhitong Financial APP learned that Shenwan Hongyuan released a research report saying that according to the "overweight" rating of 688198.SH for the first time, it is estimated that the income for 21-23 years will be 2.52company3.22 / 423 million yuan, an increase of 38.6%, 27.8% and 31.3% over the same period last year, and the net profit of its mother will be 0.55Universe 1.16 / 172 million yuan, a year-on-year increase of-3.1%, 112.2% and 48.1%, corresponding to a price-to-earnings ratio of 430,202, 137 times. With a reasonable market capitalization of 27.757 billion, there is room for 18% growth. Shen Wanhongyuan's main points are as follows: surgical biovalve faucet, occupy
Analysis
Price Target
No Data
